A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
Evopoint reveals intriguing but opaque first-in-human data for XNW27011.
But camizestrant’s use could depend on uptake of monitoring – for now.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
